Evaluation of Lubricant Eye Drops - Full Text View

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00702377

Purpose

To evaluate the safety and efficacy of two artificial tears in dry eye patients.

Condition	Intervention
Dry Eye	Drug: SYSTANE Ultra

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Tear break-up time Corneal staining Conjunctival staining Ocular symptoms and treatment satisfaction Ocular surface disease index Visual function Adverse Events [ Time Frame: From baseline ] [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	June 2008
Study Completion Date:	September 2008
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental SYSTANE Ultra	Drug: SYSTANE Ultra Lubricant Eye Drops
2: Active Comparator OPTIVE Lubricant Eye Drops (Allergan)	Drug: SYSTANE Ultra Lubricant Eye Drops

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00702377

Locations

United States, Texas
Contact Call Center for Locations
Fort Worth, Texas, United States, 76134

Sponsors and Collaborators

Alcon Research

More Information

Responsible Party:	Alcon ( Mike Christensen )
Study ID Numbers:	C-07-33
Study First Received:	June 19, 2008
Last Updated:	September 24, 2008
ClinicalTrials.gov Identifier:	NCT00702377
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Tetrahydrozoline

ClinicalTrials.gov processed this record on January 15, 2009